Clinical trials: Ovarian Cancers
Breast Cancer, Ovarian Cancer
OPTimizing Treatment Focused Genetic Testing IN Cancer
This two-part randomized controlled trial aims to evaluate the impact of pre-test video education as compared to pre-test Chatbot education.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- OPT-IN (NCT04066361)
- Testing
- Chatbot, Video Education
- Where
- United States
- Volunteers
- 301 people
- Sponsor
- Dana-Farber Cancer Institute
Polycystic Ovary Syndrome
Cardiovascular Risk Markers in Polycystic Ovary Syndrome (PCOS)
Women with polycystic ovary syndrome (PCOS) are more often overweight or obese and are more insulin resistant than women without the condition and may be at greater risk of developing cardiovascular disease.
- Trial name
- CS (NCT01195168)
- Where
- 2 sites in Ireland
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- The Adelaide and Meath Hospital
Ovarian Cancer
An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy
This project intends to evaluate the sensitivity of different Homologous Recombination Deficiency (HRD) score to Poly(ADP-ribose) polymerase inhibitor (PARPi) by retrospectively analyzing the tissue samples of patients with…
- Trial name
- NCT05255861
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xin Wu
Infertility, Polycystic Ovary Syndrome
A New Algorithm to Predict Ovarian Age
To collect data of clinical, biochemical and 3D-ultrasonographic parameters of a population of fertile women aged 18-55 in order to design a new algorithm able to predict ovarian age and to evaluate the reliability of a…
- Conditions
- Infertility, Polycystic Ovary Syndrome, Premature Ovarian Failure (POF), Ovarian Cysts
- Trial name
- OvAge (NCT02086318)
- Testing
- OvAge assessment
- Where
- Italy
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- University Magna Graecia
Breast Cancer, Ovarian Cancer
Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer
A phase I trial to determine the recommended phase two dose of the combination of carboplatin and olaparib.
- Conditions
- Breast Cancer, Ovarian Cancer, Advanced Cancer
- Trial name
- REVIVAL (NCT02418624)
- Testing
- carboplatin, olaparib
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- The Netherlands Cancer Institute
Infertility, Ovulation Induction
SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women
Efficacy and safety studies in the past have suggested that a starting dose of 75 International Unit (IU) of SJ-0021, and an increase in the dose by 37.5 IU every 7 days, are safe for treatment of subjects with ovulatory…
- Trial name
- NCT01185782
- Testing
- Gonalef® (Follitropin alfa), Purified pituitary gonadotropin (Fertinorm-P®)
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Ovarian Neoplasms
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (<1 cm) FIGO stage III and IV…
- Trial name
- NCT00718523
- Testing
- AMG 479
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 170 people
- Sponsor
- Translational Research in Oncology
Ovarian Cancer
Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
This is a single arm, multi center, exploratory clinical study to evaluate the efficacy and safety of fluzoparide combined with alpatinib as neoadjuvant therapy in patients with BRCA1/2 gene mutation or HRD gene mutation…
- Trial name
- NCT05597527
- Testing
- Fluzopari and apatinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Ovarian Cancer, Ovarian Carcinoma
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
A number of studies suggest that the combination of PARP inhibitors and antiangiogenic agents produce synergistic activities. Pamiparib is a small molecule inhibitor selectivity for both PARP1 and PARP2.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Fallopian Tube Carcinosarcoma
- Trial name
- NCT05494580
- Testing
- Pamiparib, Surufatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-sen University
Ovarian Cancer
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile.
- Trial name
- NCT05467670
- Testing
- Pembrolizumab, ALX148, Doxorubicin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Alexander B Olawaiye, MD
Ovarian Cancer
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.
- Trial name
- NCT00866697
- Testing
- Pazopanib
- Where
- 318 sites in United States, Australia and 15 more
- Volunteers
- 940 people
- Sponsor
- Novartis Pharmaceuticals
Polycystic Ovary Syndrome
Simvastatin and Metformin Therapy in PCOS Women. Prospective Randomised Trial.
The purpose of this study is to compare effects of statins (simvastatin) and metformin on clinical (menstrual cycle, excessive hair, skin problems), endocrine (androgens), metabolic (lipids, markers of systemic inflammation), and…
- Trial name
- NCT00396513
- Testing
- Simvastatin, Simvastatin and Metformin, Metformin
- Where
- Poland
- Sponsor
- Poznan University of Medical Sciences
Fallopian Tube Cancer, Ovarian Cancer
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003380
- Testing
- etoposide, pegylated liposomal doxorubicin hydrochloride
- Where
- 63 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Solid Tumors
Investigator Initiated Phase 1 Study of TBI-1301
Following pre-treatment with cyclophosphamide and/or fludarabine, NY-ESO-1-specific TCR gene transduced T lymphocytes are transferred to the patients with NY-ESO-1-expressing solid tumors.
- Trial name
- NCT02366546
- Testing
- TBI-1301, Cyclophosphamide, Fludarabine
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Mie University
Ovarian Cancer
Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy
Determination of total survival under Topotecan Monotherapy, Topotecan + Etoposide and Topotecan + Gemcitabine in second-line therapy in patient with recurrent ovarian cancer.
- Trial name
- NCT00312988
- Testing
- Hycamtin, Gemcitabine
- Where
- Germany
- Volunteers
- 450 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Cancer, Fertility
The Experience of TYAC Offered Ovarian Tissue Cryopreservation
This study looks at the experiences of teenagers and young adults who have been offered ovarian tissue cryopreservation prior to cancer treatment as a result of their cancer and/or cancer treatment putting them at…
- Trial name
- NCT02830061
- Testing
- Interviews
- Volunteers
- 12 people
- Sponsor
- University of Oxford
Ovarian Cancer, Ovarian Carcinoma
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer
- Trial name
- NCT03748186
- Testing
- STRO-002
- Where
- 27 sites in United States, Spain
- Volunteers
- 136 people
- Sponsor
- Sutro Biopharma, Inc.
BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer
This is a multicenter phase II study on trabectedin in advanced or recurrent ovarian cancer patients with BRCA mutation and BRCAness phenotype.
- Trial name
- MITO15 (NCT01772979)
- Testing
- Trabectedin
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Catholic University of the Sacred Heart
Breast Cancer, Lung Cancer
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00005023
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Sponsor
- University of Washington
Ovarian Cancer
Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.
- Trial name
- NCT06646627
- Testing
- B7-H3CART
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.